Skyscape Web Viewer : Cancer Pharmacology: An Illustrated Manual of Anticancer Drugs : Image Index

View All
Development of Biomarkers Based on Their Intended Use
Early-Phase Clinical Trials Using Adaptive Designs
Effects of the Tumor Microenvironment on Pharmacodynamics
Effects of the Tumor Microenvironment on Pharmacokinetics
Elements of an Antibody-drug Conjugate (ADC)
Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER)
Epigenetics Modifying Agents and the Mechanism of Action
Estrogen Biosynthesis from Cholesterol Precursors in Endocrine Organs
Estrogen-Dependent Tumor Growth
Ethylenimines
Examples of Boronic Acid (Left, Bortezomib) and Epoxyketone (Right, Carfilzomib) Proteasome Inhibitors
FMS-Like Tyrosine Kinase 3 (FLT3) Receptor
Folic Acid Cycle as Relevant for Conversion of Deoxyuridine Monophosphate (dUMP)
Function and Therapeutic Targeting of DNA Topoisomerase I and II
Getting to the Recommended Phase 2 Dose (Rp2d)
Hemorrhagic Cystitis Related to Cyclophosphamide and Ifosfamide
Hormones Affecting the Breast
Immune Checkpoint Inhibitors Can Cause a Wide Range of Immune-Related Adverse Effects (irAEs)
Immunomodulatory Drugs (IMiDs) with Their Structure Almost Resembling a Snowman
Indenabling Nonclinical Studies for Cancer Drugs
Inhibition of the Cell Cycle and Transcription through CDK Inhibition
Isocitrate Dehydrogenase (IDH) and Ten-Eleven Translocation 2 (TET2) Mutations
Janus Kinase (JAK)/Signal Transducer and Activator of Transcription (STAT) Pathway
Mechanism of Action for High-Dose Interleukin
Mechanism of Action of Cyclophosphamide
Mechanism of Action of DNA Alkylation by Nitrogen Mustards
Mechanism of Action of High-Dose Cyclophosphamide Graft-Versus-Host Disease (GVHD) Prophylaxis
Mechanism of Action of Mycophenolate Mofetil (CellCept)
Mechanism of Action of Nucleoside Analogs (NA)
Mechanism of Action of Topoisomerase Inhibitors